Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence
DRUG: Adebrelimab, Apatinib, Gemcitabine, cisplatin
1-year EFS rate, 1-year event-free survival rate, Up to approximately 3 years
R0 Resection rate, R0 Resection rate, Up to approximately 3 years|EFS, Event-free survival, Up to approximately 3 years|RFS, Recurrence-free survival, Up to approximately 3 years|OS, Overall survival, Up to approximately 3 years
This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.